首页 > 最新文献

Methods in molecular medicine最新文献

英文 中文
Clinical Validation of a Whole Exome Sequencing Pipeline 全外显子组测序管道的临床验证
Pub Date : 2020-07-15 DOI: 10.5772/intechopen.93251
D. Prosser, I. Raja, Kelly Kolkiewicz, A. Milano, D. Love
Establishing whole exome sequencing (WES) in an accredited clinical diagnostic space is challenging. The validation (as opposed to verification) of an approach that will lead to clinical reports requires adhering to international guidelines and recommendations and developing a robust analytical pipeline that can scale due to the increasing clinical demand for comprehensive gene screening. This chapter will present a step-wise approach to WES validation that any laboratory can follow. The focus will be on highlighting the pivotal technical issues that must be addressed in validating WES and the analytical tools and QC metrics that must be considered before implementing WES in a clinical environment.
建立全外显子组测序(WES)在一个认可的临床诊断空间是具有挑战性的。验证(而不是验证)一种将导致临床报告的方法需要遵守国际指南和建议,并开发一个强大的分析管道,可以根据临床对全面基因筛查的需求不断增加而扩展。本章将介绍一个循序渐进的WES验证方法,任何实验室都可以遵循。重点是强调在验证WES时必须解决的关键技术问题,以及在临床环境中实施WES之前必须考虑的分析工具和质量控制指标。
{"title":"Clinical Validation of a Whole Exome Sequencing Pipeline","authors":"D. Prosser, I. Raja, Kelly Kolkiewicz, A. Milano, D. Love","doi":"10.5772/intechopen.93251","DOIUrl":"https://doi.org/10.5772/intechopen.93251","url":null,"abstract":"Establishing whole exome sequencing (WES) in an accredited clinical diagnostic space is challenging. The validation (as opposed to verification) of an approach that will lead to clinical reports requires adhering to international guidelines and recommendations and developing a robust analytical pipeline that can scale due to the increasing clinical demand for comprehensive gene screening. This chapter will present a step-wise approach to WES validation that any laboratory can follow. The focus will be on highlighting the pivotal technical issues that must be addressed in validating WES and the analytical tools and QC metrics that must be considered before implementing WES in a clinical environment.","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80476633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating Evolutionary Genetics to Medical Genomics: Evolutionary Approaches to Investigate Disease-Causing Variants 整合进化遗传学到医学基因组学:研究致病变异的进化方法
Pub Date : 2020-07-15 DOI: 10.5772/intechopen.92738
U. Sezerman, T. Bozkurt, F. S. Isleyen
In recent years, next-generation sequencing (NGS) platforms that facilitate generation of a vast amount of genomic variation data have become widely used for diagnostic purposes in medicine. However, identifying the potential effects of the variations and their association with a particular disease phenotype is the main challenge in this field. Several strategies are used to discover the causative mutations among hundreds of variants of uncertain significance. Incorporating information from healthy population databases, other organisms’ databases, and computational prediction tools are evolution-based strategies that give valuable insight to interpret the variant pathogenicity. In this chapter, we first provide an overview of NGS analysis workflow. Then, we review how evolutionary principles can be integrated into the prioritization schemes of analyzed variants. Finally, we present an example of a real-life case where the use of evolutionary genetics information facilitated the discovery of disease-causing variants in medical genomics.
近年来,下一代测序(NGS)平台促进了大量基因组变异数据的生成,已广泛用于医学诊断目的。然而,确定变异的潜在影响及其与特定疾病表型的关联是该领域的主要挑战。在数百个意义不确定的变异中,使用了几种策略来发现致病突变。结合来自健康人群数据库、其他生物数据库和计算预测工具的信息是基于进化的策略,为解释变异致病性提供了有价值的见解。在本章中,我们首先概述了NGS分析工作流程。然后,我们回顾了如何将进化原理集成到分析变量的优先级方案中。最后,我们提出了一个现实生活中的例子,其中使用进化遗传学信息促进了医学基因组学中致病变异的发现。
{"title":"Integrating Evolutionary Genetics to Medical Genomics: Evolutionary Approaches to Investigate Disease-Causing Variants","authors":"U. Sezerman, T. Bozkurt, F. S. Isleyen","doi":"10.5772/intechopen.92738","DOIUrl":"https://doi.org/10.5772/intechopen.92738","url":null,"abstract":"In recent years, next-generation sequencing (NGS) platforms that facilitate generation of a vast amount of genomic variation data have become widely used for diagnostic purposes in medicine. However, identifying the potential effects of the variations and their association with a particular disease phenotype is the main challenge in this field. Several strategies are used to discover the causative mutations among hundreds of variants of uncertain significance. Incorporating information from healthy population databases, other organisms’ databases, and computational prediction tools are evolution-based strategies that give valuable insight to interpret the variant pathogenicity. In this chapter, we first provide an overview of NGS analysis workflow. Then, we review how evolutionary principles can be integrated into the prioritization schemes of analyzed variants. Finally, we present an example of a real-life case where the use of evolutionary genetics information facilitated the discovery of disease-causing variants in medical genomics.","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"234 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76803948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Perspectives in Personalization of Therapy for Hematological Cancers 血液病个体化治疗的新视角
Pub Date : 2020-05-01 DOI: 10.5772/intechopen.91957
M. Rogalińska
A progress in treatment of hematological cancers was achieved. Unfortunately, some youngsters, because of rare genetic alterations that are not easy to detect, as well as heavily pretreated old patients, because of coexisting diseases that lead to changes in patient metabolism, do not respond to therapy. Moreover, sometimes familiar diversities and alterations on genetic or epigenetic level that could be transferred on diversities in metabolism or cell signaling might be a reason why patients do not respond to therapy. Interestingly, for older patients a resistance to therapy could also occur as a reason of drug cross-reactivity. For designing of effective anticancer therapy for patient with chronic lymphocytic leukemia before drug administration, patient’s leukemic cell response to anticancer drug(s) should be checked. Moreover, for patient response to treatment, also drugs prescribed previously by other medical doctors or even patients’ diet could be important for achieving therapeutic success of therapy. Therefore it is important to choose the effective drugs before their administration to patient that will improve treatment efficacy and exclude resistance to therapy. It must be stated that the special attention for personalized therapy tests should be focused on patients previously resistant to therapy, more sensitive to drugs or heavily pretreated.
在血液病治疗方面取得进展。不幸的是,一些年轻人,由于罕见的不易检测的基因改变,以及大量预处理的老年患者,由于共存的疾病导致患者代谢的变化,对治疗没有反应。此外,有时在遗传或表观遗传水平上熟悉的多样性和改变可能会转移到代谢或细胞信号的多样性上,这可能是患者对治疗没有反应的原因。有趣的是,对于老年患者,对治疗的抵抗也可能作为药物交叉反应的原因发生。为了在给药前对慢性淋巴细胞白血病患者设计有效的抗癌治疗方案,应检查患者白血病细胞对抗癌药物的反应。此外,对于患者对治疗的反应,其他医生以前开过的药物甚至患者的饮食对治疗的成功也很重要。因此,在给患者用药前选择有效的药物,以提高治疗效果,排除治疗耐药是非常重要的。必须指出,对个性化治疗试验的特别关注应集中在以前对治疗有耐药性、对药物更敏感或进行了大量预处理的患者身上。
{"title":"New Perspectives in Personalization of Therapy for Hematological Cancers","authors":"M. Rogalińska","doi":"10.5772/intechopen.91957","DOIUrl":"https://doi.org/10.5772/intechopen.91957","url":null,"abstract":"A progress in treatment of hematological cancers was achieved. Unfortunately, some youngsters, because of rare genetic alterations that are not easy to detect, as well as heavily pretreated old patients, because of coexisting diseases that lead to changes in patient metabolism, do not respond to therapy. Moreover, sometimes familiar diversities and alterations on genetic or epigenetic level that could be transferred on diversities in metabolism or cell signaling might be a reason why patients do not respond to therapy. Interestingly, for older patients a resistance to therapy could also occur as a reason of drug cross-reactivity. For designing of effective anticancer therapy for patient with chronic lymphocytic leukemia before drug administration, patient’s leukemic cell response to anticancer drug(s) should be checked. Moreover, for patient response to treatment, also drugs prescribed previously by other medical doctors or even patients’ diet could be important for achieving therapeutic success of therapy. Therefore it is important to choose the effective drugs before their administration to patient that will improve treatment efficacy and exclude resistance to therapy. It must be stated that the special attention for personalized therapy tests should be focused on patients previously resistant to therapy, more sensitive to drugs or heavily pretreated.","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85875796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Medicines for Parasitic Diseases 寄生虫病分子药物
Pub Date : 2020-04-10 DOI: 10.5772/intechopen.91956
Bhawana Singh
Being the cause for significant amount of morbidities and mortalities, parasitic diseases remain the major challenge for the healthcare community due to the limitations associated with the current chemotherapeutics. Drug discovery/invention can be achieved by collaborative efforts of biotechnologists and pharmacists for identifying potential candidates and successfully turn them into medicine for improving the healthcare system. Although molecular medicine for disease intervention is still in its infancy, however, significant research works and successful trials in short span of time have made it broadly accepted among the scientific community. This chapter identifies different molecular medicine approaches for dealing with parasites that have been coming up on the horizon with the new technological advances in bioinformatics and in the field of omics. With the better understanding of the genomics, molecular medicine field has not only raised hopes to deal with parasitic infections but also accelerated the development of personalized medicine. This will provide a targeted approach for identifying the druggable targets and their pathophysiological importance for disease intervention.
寄生虫病是造成大量发病率和死亡率的原因,由于目前化疗的局限性,寄生虫病仍然是医疗界面临的主要挑战。药物发现/发明可以通过生物技术专家和药剂师的共同努力来实现,以确定潜在的候选药物,并成功地将其转化为改善医疗保健系统的药物。虽然分子医学在疾病干预方面仍处于起步阶段,但短时间内大量的研究工作和成功的试验使其在科学界得到了广泛的认可。随着生物信息学和组学领域的新技术进步,本章确定了处理寄生虫的不同分子医学方法。随着对基因组学的深入了解,分子医学领域不仅为应对寄生虫感染带来了希望,而且加速了个性化医疗的发展。这将为确定药物靶标及其对疾病干预的病理生理重要性提供一种有针对性的方法。
{"title":"Molecular Medicines for Parasitic Diseases","authors":"Bhawana Singh","doi":"10.5772/intechopen.91956","DOIUrl":"https://doi.org/10.5772/intechopen.91956","url":null,"abstract":"Being the cause for significant amount of morbidities and mortalities, parasitic diseases remain the major challenge for the healthcare community due to the limitations associated with the current chemotherapeutics. Drug discovery/invention can be achieved by collaborative efforts of biotechnologists and pharmacists for identifying potential candidates and successfully turn them into medicine for improving the healthcare system. Although molecular medicine for disease intervention is still in its infancy, however, significant research works and successful trials in short span of time have made it broadly accepted among the scientific community. This chapter identifies different molecular medicine approaches for dealing with parasites that have been coming up on the horizon with the new technological advances in bioinformatics and in the field of omics. With the better understanding of the genomics, molecular medicine field has not only raised hopes to deal with parasitic infections but also accelerated the development of personalized medicine. This will provide a targeted approach for identifying the druggable targets and their pathophysiological importance for disease intervention.","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"5 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82834761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Landscape Genetics: From Classic Molecular Markers to Genomics 景观遗传学:从经典分子标记到基因组学
Pub Date : 2020-04-08 DOI: 10.5772/intechopen.92022
E. R. Konzen, M. Zucchi
Landscape genetics combines population genetics and landscape ecology to understand processes that shape the distribution and organization of human, animal, or plant populations. This field of genetics emerged from the availability of several studies with classical molecular markers, such as isozymes, RAPD, AFLP, and microsatellites. Population genetic studies enabled the detection of population structure with those markers, but a more comprehensive analysis of natural populations was only possible with the development of statistical methods that combined both molecular data and environmental variables. Ultimately, the rapid development of sequencing technologies allowed studies at the genomic level, augmenting the resolution of association with environment factors. This chapter outlines basic concepts in landscape genetics, the main statistical methods used so far, and the perspectives of this field of knowledge into strategies for conservation of natural populations of plant and animal species. Moreover, we briefly describe the application of the field to understand historical human migration processes as well as how some diseases are spread throughout the world.
景观遗传学结合了种群遗传学和景观生态学来理解塑造人类、动物或植物种群分布和组织的过程。这一领域的遗传学兴起于一些经典分子标记的研究,如同工酶、RAPD、AFLP和微卫星。种群遗传研究可以用这些标记来探测种群结构,但是只有发展出结合分子数据和环境变量的统计方法,才能对自然种群进行更全面的分析。最终,测序技术的快速发展使基因组水平的研究成为可能,增加了与环境因素关联的分辨率。本章概述了景观遗传学的基本概念,迄今为止使用的主要统计方法,以及这一知识领域对植物和动物自然种群保护策略的看法。此外,我们简要地描述了该领域的应用,以了解历史上的人类迁移过程以及一些疾病如何在世界范围内传播。
{"title":"Landscape Genetics: From Classic Molecular Markers to Genomics","authors":"E. R. Konzen, M. Zucchi","doi":"10.5772/intechopen.92022","DOIUrl":"https://doi.org/10.5772/intechopen.92022","url":null,"abstract":"Landscape genetics combines population genetics and landscape ecology to understand processes that shape the distribution and organization of human, animal, or plant populations. This field of genetics emerged from the availability of several studies with classical molecular markers, such as isozymes, RAPD, AFLP, and microsatellites. Population genetic studies enabled the detection of population structure with those markers, but a more comprehensive analysis of natural populations was only possible with the development of statistical methods that combined both molecular data and environmental variables. Ultimately, the rapid development of sequencing technologies allowed studies at the genomic level, augmenting the resolution of association with environment factors. This chapter outlines basic concepts in landscape genetics, the main statistical methods used so far, and the perspectives of this field of knowledge into strategies for conservation of natural populations of plant and animal species. Moreover, we briefly describe the application of the field to understand historical human migration processes as well as how some diseases are spread throughout the world.","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75478474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
DNA-mediated gene transfer. dna介导的基因转移。
Pub Date : 2020-02-02 DOI: 10.1002/9783527678679.dg03327
A. J. O'Donnell
{"title":"DNA-mediated gene transfer.","authors":"A. J. O'Donnell","doi":"10.1002/9783527678679.dg03327","DOIUrl":"https://doi.org/10.1002/9783527678679.dg03327","url":null,"abstract":"","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"16 1","pages":"259-66"},"PeriodicalIF":0.0,"publicationDate":"2020-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83184701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Assay of air sample eluates. 空气样品洗脱液的测定。
Pub Date : 2008-01-01 DOI: 10.1007/978-1-59745-366-0_18
Anne Renström, Susan Gordon

After air sampling and elution, the air sample eluate contains an unknown amount of allergens together with other materials. The proteins of interest can be quantified using immunoassays, which are sensitive, economical, and can be used for high throughput. However, the amount of antigen or allergen in an air sample may be very low and consequently the assays must be very sensitive and specific. Immunoassays use antibodies both to capture and visualize the chosen antigen. High specificity and sensitivity can best be achieved by the use of purified, characterized, and specific antibodies. It is possible to choose between a wide variety of assay setups and reagents. The method described here has been developed for the measurement of airborne rodent allergens. It is a noncompetitive, two-site (sandwich) EIA that utilizes polyclonal antibodies. The detection system uses biotin and streptavidin for increased sensitivity and horseradish peroxidase as the substrate with 3,3',5,5'-tetramethylbenzidine (TMB) for rapid color development and high sensitivity.

经过空气取样和洗脱后,空气样品洗脱液与其他物质一起含有未知数量的过敏原。感兴趣的蛋白质可以用免疫测定法定量,这是敏感的,经济的,并且可以用于高通量。然而,空气样本中抗原或过敏原的含量可能很低,因此测定必须非常敏感和特异性。免疫测定法使用抗体来捕获和可视化所选抗原。高特异性和敏感性可以最好地通过使用纯化,表征和特异性抗体来实现。可以在各种各样的测定装置和试剂之间进行选择。本文所描述的方法是为测量空气传播的啮齿动物过敏原而开发的。它是一种利用多克隆抗体的非竞争性、双位点(三明治)EIA。检测系统采用生物素和链亲和素提高灵敏度,以辣根过氧化物酶为底物,以3,3',5,5'-四甲基联苯胺(TMB)快速显色,灵敏度高。
{"title":"Assay of air sample eluates.","authors":"Anne Renström,&nbsp;Susan Gordon","doi":"10.1007/978-1-59745-366-0_18","DOIUrl":"https://doi.org/10.1007/978-1-59745-366-0_18","url":null,"abstract":"<p><p>After air sampling and elution, the air sample eluate contains an unknown amount of allergens together with other materials. The proteins of interest can be quantified using immunoassays, which are sensitive, economical, and can be used for high throughput. However, the amount of antigen or allergen in an air sample may be very low and consequently the assays must be very sensitive and specific. Immunoassays use antibodies both to capture and visualize the chosen antigen. High specificity and sensitivity can best be achieved by the use of purified, characterized, and specific antibodies. It is possible to choose between a wide variety of assay setups and reagents. The method described here has been developed for the measurement of airborne rodent allergens. It is a noncompetitive, two-site (sandwich) EIA that utilizes polyclonal antibodies. The detection system uses biotin and streptavidin for increased sensitivity and horseradish peroxidase as the substrate with 3,3',5,5'-tetramethylbenzidine (TMB) for rapid color development and high sensitivity.</p>","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"138 ","pages":"217-25"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-1-59745-366-0_18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27523989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Conjugation of haptens. 半抗原缀合。
Pub Date : 2008-01-01 DOI: 10.1007/978-1-59745-366-0_14
Ranulfo Lemus, Meryl H Karol

Many naturally occurring proteins, peptides, carbohydrates, nucleic acids, and lipids, as well as synthetic peptides, are successful immunogens. To elicit an immune response, a compound must contain an antigenic determinant or epitope and must be of sufficient size to initiate lymphocyte activation necessary for an antibody response. In practice, small chemical compounds (haptens) are generally not good immunogens. However, when attached to macromolecules (carriers), they can become immunogenic. An immunogen must have epitopes that can be recognized by antigen-presenting cells and a T-cell receptor, and it must be degradable. Haptens and corresponding hapten-carrier conjugates have been essential to the development of sensitive quantitative and qualitative immunoassays. In the design of hapten conjugates, consideration must be given to the hapten, the carrier, the coupling strategy, and the hapten density because the amount of hapten attached to the carrier influences the strength of the immune response directed toward the newly created antigenic determinant. Hence the haptenic density of the conjugate is also important in the development of immunoassays. The optimal epitope density of a conjugate to elicit either a strong immune response or provide the best immunoassay is dependent on the structure of the epitope and the nature of the immunoassay. The aim of this chapter is to describe the diverse techniques used to couple haptens to carriers and provide guidance in the selection of the most appropriate procedure for a particular hapten.

许多天然存在的蛋白质、多肽、碳水化合物、核酸和脂质,以及合成的多肽,都是成功的免疫原。为了引起免疫应答,化合物必须含有抗原决定因子或表位,并且必须有足够的大小来启动抗体应答所必需的淋巴细胞激活。在实践中,小化合物(半抗原)通常不是好的免疫原。然而,当与大分子(载体)结合时,它们可以具有免疫原性。免疫原必须具有抗原呈递细胞和t细胞受体能够识别的表位,并且它必须是可降解的。半抗原和相应的半抗原载体偶联物对发展敏感的定量和定性免疫分析至关重要。在设计半抗原偶联物时,必须考虑到半抗原、载体、偶联策略和半抗原密度,因为半抗原附着在载体上的数量会影响针对新产生的抗原决定因子的免疫反应的强度。因此偶联物的半抗原密度在免疫测定的发展中也很重要。缀合物的最佳表位密度是否能引起强烈的免疫反应或提供最佳的免疫测定取决于表位的结构和免疫测定的性质。本章的目的是描述用于半抗原与载体偶联的各种技术,并为特定半抗原选择最合适的程序提供指导。
{"title":"Conjugation of haptens.","authors":"Ranulfo Lemus,&nbsp;Meryl H Karol","doi":"10.1007/978-1-59745-366-0_14","DOIUrl":"https://doi.org/10.1007/978-1-59745-366-0_14","url":null,"abstract":"<p><p>Many naturally occurring proteins, peptides, carbohydrates, nucleic acids, and lipids, as well as synthetic peptides, are successful immunogens. To elicit an immune response, a compound must contain an antigenic determinant or epitope and must be of sufficient size to initiate lymphocyte activation necessary for an antibody response. In practice, small chemical compounds (haptens) are generally not good immunogens. However, when attached to macromolecules (carriers), they can become immunogenic. An immunogen must have epitopes that can be recognized by antigen-presenting cells and a T-cell receptor, and it must be degradable. Haptens and corresponding hapten-carrier conjugates have been essential to the development of sensitive quantitative and qualitative immunoassays. In the design of hapten conjugates, consideration must be given to the hapten, the carrier, the coupling strategy, and the hapten density because the amount of hapten attached to the carrier influences the strength of the immune response directed toward the newly created antigenic determinant. Hence the haptenic density of the conjugate is also important in the development of immunoassays. The optimal epitope density of a conjugate to elicit either a strong immune response or provide the best immunoassay is dependent on the structure of the epitope and the nature of the immunoassay. The aim of this chapter is to describe the diverse techniques used to couple haptens to carriers and provide guidance in the selection of the most appropriate procedure for a particular hapten.</p>","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"138 ","pages":"167-82"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-1-59745-366-0_14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27522385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 26
Understanding of the molecular mechanisms of allergy. 了解过敏的分子机制。
Pub Date : 2008-01-01 DOI: 10.1007/978-1-59745-366-0_1
Meinir Jones

The prevalence of allergic disease has dramatically increased over the past 30 years in Westernised countries. It is unlikely that the rapid increase in the prevalence of allergic disease is the result of genetic changes, which highlights the importance of environmental factors in the development of allergic disease. The 'hygiene hypothesis' was put forward in 1989 and focused attention on the notion that exposure to microbes and their products in early life can modify the risk for development of allergic disease. Infections were thought to polarize the immunological response towards a Th2-mediated immune responses causing allergic disease. However it is likely that the Th1/Th2 imbalance is too simplistic to explain the increased prevalence of allergic disease. Current research is focusing on understanding the role of T regulatory cells in inducing a state of tolerance and the resulting modified Th2 response observed in natural and induced tolerance.

在过去的30年里,过敏性疾病在西方国家的发病率急剧上升。变应性疾病患病率的快速增加不太可能是遗传变化的结果,这突出了环境因素在变应性疾病发展中的重要性。“卫生假说”是1989年提出的,主要关注的是在生命早期接触微生物及其产物可以改变过敏性疾病发展的风险。感染被认为使免疫反应向th2介导的免疫反应极化,导致过敏性疾病。然而,Th1/Th2失衡可能过于简单,无法解释过敏性疾病患病率增加的原因。目前的研究重点是了解T调节细胞在诱导耐受性状态中的作用,以及在自然和诱导耐受性中观察到的由此产生的修饰Th2反应。
{"title":"Understanding of the molecular mechanisms of allergy.","authors":"Meinir Jones","doi":"10.1007/978-1-59745-366-0_1","DOIUrl":"https://doi.org/10.1007/978-1-59745-366-0_1","url":null,"abstract":"<p><p>The prevalence of allergic disease has dramatically increased over the past 30 years in Westernised countries. It is unlikely that the rapid increase in the prevalence of allergic disease is the result of genetic changes, which highlights the importance of environmental factors in the development of allergic disease. The 'hygiene hypothesis' was put forward in 1989 and focused attention on the notion that exposure to microbes and their products in early life can modify the risk for development of allergic disease. Infections were thought to polarize the immunological response towards a Th2-mediated immune responses causing allergic disease. However it is likely that the Th1/Th2 imbalance is too simplistic to explain the increased prevalence of allergic disease. Current research is focusing on understanding the role of T regulatory cells in inducing a state of tolerance and the resulting modified Th2 response observed in natural and induced tolerance.</p>","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"138 ","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-1-59745-366-0_1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27522435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
A method to assay inhibitors of DNA polymerase IIIC activity. 测定DNA聚合酶IIIC活性抑制剂的方法。
Pub Date : 2008-01-01 DOI: 10.1007/978-1-59745-246-5_3
Michelle M Butler, George E Wright

The need for new drugs to treat infections caused by antibiotic-resistant bacterial strains has prompted many studies to identify novel targets in pathogenic bacteria. Among the three DNA polymerases expressed by bacteria, one of these, designated pol III, is responsible for DNA replication and growth of bacteria and, therefore, warrants consideration as a drug target. However, the pol III enzymes of Gram-positive and Gram-negative species are quite different, and the Gram-positive enzyme pol IIIC has been more extensively studied as a drug target than the Gram-negative enzyme pol IIIE.DNA polymerases are unique enzymes with respect to the five substrates (four dNTPs, one of which is radiolabeled, and primer:template DNA) that they typically utilize. Variations of the assay, e.g., by leaving out one dNTP but allowing measurable incorporation of the remaining substrates, or use of homopolymer primer:templates, may be used to simplify the assay or to obtain mechanistic information about inhibitors. Use of gel analysis of primer extension assays can also be applied to study alternate substrates of DNA polymerases. Methods to isolate pol IIIC from Gram-positive bacterial cells and to clone and express the polC gene are described in this chapter. In addition, the assay conditions commonly used to identify and study the mechanism of inhibitors of pol IIIC are emphasized.

需要新的药物来治疗抗生素耐药菌株引起的感染,这促使许多研究在致病菌中确定新的靶点。在细菌表达的三种DNA聚合酶中,其中一种称为pol III的酶负责细菌的DNA复制和生长,因此值得考虑作为药物靶点。然而,革兰氏阳性和革兰氏阴性物种的pol III酶有很大的不同,革兰氏阳性酶pol IIIC作为药物靶点的研究比革兰氏阴性酶pol IIIE更广泛。DNA聚合酶是它们通常利用的五种底物(四种dNTPs,其中一种是放射性标记的,引物:模板DNA)的独特酶。分析的变化,例如,通过省略一个dNTP但允许可测量的剩余底物的掺入,或使用均聚物引物模板,可用于简化分析或获得有关抑制剂的机制信息。使用凝胶分析引物延伸试验也可以应用于研究DNA聚合酶的替代底物。本文介绍了从革兰氏阳性细菌细胞中分离pol IIIC、克隆表达polC基因的方法。此外,还着重介绍了鉴定和研究酚IIIC抑制剂作用机制的常用检测条件。
{"title":"A method to assay inhibitors of DNA polymerase IIIC activity.","authors":"Michelle M Butler,&nbsp;George E Wright","doi":"10.1007/978-1-59745-246-5_3","DOIUrl":"https://doi.org/10.1007/978-1-59745-246-5_3","url":null,"abstract":"<p><p>The need for new drugs to treat infections caused by antibiotic-resistant bacterial strains has prompted many studies to identify novel targets in pathogenic bacteria. Among the three DNA polymerases expressed by bacteria, one of these, designated pol III, is responsible for DNA replication and growth of bacteria and, therefore, warrants consideration as a drug target. However, the pol III enzymes of Gram-positive and Gram-negative species are quite different, and the Gram-positive enzyme pol IIIC has been more extensively studied as a drug target than the Gram-negative enzyme pol IIIE.DNA polymerases are unique enzymes with respect to the five substrates (four dNTPs, one of which is radiolabeled, and primer:template DNA) that they typically utilize. Variations of the assay, e.g., by leaving out one dNTP but allowing measurable incorporation of the remaining substrates, or use of homopolymer primer:templates, may be used to simplify the assay or to obtain mechanistic information about inhibitors. Use of gel analysis of primer extension assays can also be applied to study alternate substrates of DNA polymerases. Methods to isolate pol IIIC from Gram-positive bacterial cells and to clone and express the polC gene are described in this chapter. In addition, the assay conditions commonly used to identify and study the mechanism of inhibitors of pol IIIC are emphasized.</p>","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"142 ","pages":"25-36"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-1-59745-246-5_3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27404312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
期刊
Methods in molecular medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1